Literature DB >> 28335059

Retrospective Evaluation of Percutaneous Access for TEVAR and EVAR: Time to Make it the Standard Approach?

Rohit Philip Thomas1, Tobias Kowald1, Bernhard Schmuck1, Osama Eldergash1, Andreas Klausen2, Valentin Dikov3, Jerry Easo3, Ajay Chavan1.   

Abstract

Introduction To evaluate the safety of percutaneous endovascular aortic repair and the relationship of access site characteristics to complications Materials and Methods All patients undergoing percutaneous TEVAR, EVAR and FEVAR procedures from January 2010 to May 2016 were retrospectively analysed for incidence of complications and their relationship to various access site characteristics like access artery size, degree of vessel calcification, skin to artery distance and sheath to artery ratio. Hemostasis occurring within 15 min after suture closure with or without manual compression was defined as primary hemostasis. Results 92 patients with 142 femoral access sites were included in the study. Median follow-up was 28.13 months (range 2.5 - 76.7 months, Mean 32.39, SD - 21.66 months). Introducer system size ranged from 12F to 25F. Primary haemostasis was achieved in 97.1 % (138/142) of the total femoral access sites. Four access sites (2.8 %) had to be closed surgically; in all 4 cases the introducer systems was ≥ 18F. Two of these access sites had been operated upon previously. Late complications including inguinal hematoma (n = 7), wound infection (n = 1), scrotal hematoma (n = 1), pseudoaneurysm (n = 4) and late bleeding (n = 4) occurred in 17 access sites (11.9 %), of which 13 were managed conservatively. On account of the low complication rate, no correlation between the evaluated variables and observed complications could be established. Conclusion Percutaneous endovascular aortic repair is feasible and safe irrespective of the size of the introducer sheath and the nature of aorto-iliac pathology. The technical success rate is high and the incidence of complications is low. Early complications are most often associated with sheath sizes ≥ 18 F. The majority of the late complications can be treated conservatively. Key points:  · Percutaneous endovascular aortic repair is feasible and safe.. · Technical success rate is high and complication rate is low.. · Vascular closure device failure in the occasional patient may necessitate surgical intervention.. Citation Format · Thomas RP, Kowald T, Schmuck B et al. Retrospective Evaluation of Percutaneous Access for TEVAR and EVAR: Time to Make it the Standard Approach?. Fortschr Röntgenstr 2017; 189: 347 - 355. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2017        PMID: 28335059     DOI: 10.1055/s-0043-101387

Source DB:  PubMed          Journal:  Rofo        ISSN: 1438-9010


  5 in total

1.  Comparison of percutaneous and cutdown access‑related minor complications after endovascular aortic repair.

Authors:  Artur Rebelo; Patrick Voss; Ulrich Ronellenfitsch; Carsten Sekulla; Jörg Ukkat
Journal:  Exp Ther Med       Date:  2022-08-17       Impact factor: 2.751

Review 2.  [Endovascular aneurysm repair (EVAR) : Complication management].

Authors:  S Amin; J Schnabel; O Eldergash; A Chavan
Journal:  Radiologe       Date:  2018-09       Impact factor: 0.635

Review 3.  Thoracic Trauma: Aortic Injuries.

Authors:  Akhil Monga; Santosh B Patil; Mathew Cherian; Santhosh Poyyamoli; Pankaj Mehta
Journal:  Semin Intervent Radiol       Date:  2021-04-15       Impact factor: 1.513

4.  Percutaneous endovascular abdominal aortic aneurysm repair with monitored anesthesia care decreases operative time but not pulmonary complications.

Authors:  Joshua P Kronenfeld; Emily L Ryon; Alex Lall; Naixin Kang; Stefan Kenel-Pierre; Hilene DeAmorim; Jorge Rey; John Karwowski; Arash Bornak
Journal:  Vascular       Date:  2021-05-03       Impact factor: 1.105

5.  Comparison of Early Efficacy of the Percutaneous Presuture Technique with the Femoral Artery Incision Technique in Endovascular Aortic Repair under Local Anesthesia for Uncomplicated Type B Aortic Dissection.

Authors:  Qingsong Wu; Debin Jiang; Xiaochai Lv; Jiaxin Zhang; Rongda Huang; Zhihuang Qiu; Liangwan Chen
Journal:  J Interv Cardiol       Date:  2022-08-22       Impact factor: 1.776

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.